Literature DB >> 15878260

Surgical quality assurance in rectal cancer treatment: the key to improved outcome.

K C M J Peeters1, C J H van de Velde.   

Abstract

Surgery is the key to cure for patients with rectal cancer. Surgical techniques are evolving with conventional blunt dissection being increasingly abandoned for the sake of total mesorectal excision (TME), leading to favourable clinical and functional outcome. Surgical quality assurance programmes, involving training of general surgeons to adopt the TME technique, have proven to be feasible and result in improved outcome compared to historical controls. In this overview, developments in rectal cancer treatment are highlighted, the relation of surgeon and/or hospital volume with treatment outcome is discussed, and future directions in optimising rectal cancer treatment are considered.

Entities:  

Mesh:

Year:  2005        PMID: 15878260     DOI: 10.1016/j.ejso.2005.02.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  Successful rectal cancer local recurrence radiofrequency ablation.

Authors:  C Bueno Muiño; J A García-Sáenz; E Santos Martín; J Sastre; J Mayol; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

2.  Evaluation of quality indicators following implementation of total mesorectal excision in primarily resected rectal cancer changed future management.

Authors:  Paul M Schneider; Daniel Vallbohmer; Yvonne Ploenes; Georg Lurje; Ralf Metzger; Frederike C Ling; Jan Brabender; Uta Drebber; Arnulf H Hoelscher
Journal:  Int J Colorectal Dis       Date:  2011-02-22       Impact factor: 2.571

3.  Morbidity and Mortality conference as part of PDCA cycle to decrease anastomotic failure in colorectal surgery.

Authors:  Peter Vogel; Georgi Vassilev; Bernd Kruse; Yesim Cankaya
Journal:  Langenbecks Arch Surg       Date:  2011-07-16       Impact factor: 3.445

Review 4.  Intentionally curative treatment of locally recurrent rectal cancer: a systematic review.

Authors:  Pieter J Tanis; Annemiek Doeksen; J Jan B van Lanschot
Journal:  Can J Surg       Date:  2013-04       Impact factor: 2.089

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.